Inhibition of epidermal growth factor receptor over-expressing cancer cells by the aphorphine-type isoquinoline

Related Experiment Video

Updated: Jun 17, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

V Badireenath Konkimalla1, Thomas Efferth

  • 1German Cancer Research Center, Heidelberg, Germany.

Biochemical Pharmacology
|December 17, 2009
PubMed

Insights

Dicentrine shows preferential toxicity against EGFR-mutated cancer cells. This novel compound activates DNA damage response and cell cycle arrest, offering a potential new therapy for resistant tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal Growth Factor Receptor (EGFR) is a key target in cancer therapy.
  • Resistance to EGFR tyrosine kinase inhibitors arises from EGFR mutations.
  • Novel inhibitors are needed to overcome treatment resistance.

Purpose of the Study:

  • To identify novel EGFR tyrosine kinase inhibitors.
  • To investigate the anti-cancer effects of dicentrine.
  • To explore the mechanisms underlying dicentrine's cytotoxicity.

Main Methods:

  • Cell culture of U87MG cells with and without EGFR expression vector.
  • Cytotoxicity assays to evaluate dicentrine's effect.
  • Microarray-based mRNA expression profiling to analyze cellular pathways.

Main Results:

  • Dicentrine exhibited preferential cytotoxicity in EGFR-mutated cells.
  • Dicentrine induced DNA damage response, including BRCA1 and p53 signaling.
  • Cell cycle regulation pathways (G1/S and G2/M) were activated.
  • Aryl hydrocarbon receptor pathways were also modulated.

Conclusions:

  • Dicentrine demonstrates potential as a therapeutic agent against EGFR-mutant tumors.
  • Its mechanism involves DNA intercalation and topoisomerase inhibition, leading to DNA damage.
  • Dicentrine induces cell cycle arrest, contributing to its anti-cancer activity.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...